TNFSF11 and breast carcinoma: This review provides a parallel perspective of the pre-clinical and clinical evidence of RANKL/RANK pathway in cancer-induced BM, breast cancer (BCa) onset and progression, and immune modulation (Figure 1), exploring the (potential) efficacy of RANKL inhibition in all cancer stages.